Optimal Anticoagulation Strategies for
Stroke Prevention in Atrial Fibrillation

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 15, 2017 to January 31, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Boehringer Ingelheim Pharmaceuticals and Bristol-Myers Squibb

Description:
Atrial fibrillation (AF) is a common type of arrhythmia affecting both men and women, and the incidence increases with age. AF may be diagnosed based on tests, such as an EKG (electrocardiogram), ECG (echocardiography), stress test, blood tests, chests x-rays, a special monitor to record the heart’s rhythms, by physical exam, and medical and family histories. Preventing blood clots (thromboembolism), and thus strokes, may be the most important part of treating atrial fibrillation. The proven therapy is to prescribe anticoagulants, or blood thinners, to prevent blood clots. However studies have found that a significant number of patients in the US do not receive adequate therapy for stroke prevention and additionally, there are multiple concerns regarding blood thinners. Updates for emerging therapeutic agents for stroke prevention in AF patients will be reviewed along with newer anti-coagulants and management/treatment algorithms.

Upon Completion of this activity, participants will be able to:

  • Analyze the safety and efficacy of novel oral anticoagulants (NOACs) for the treatment and prevention of stroke in atrial fibrillation

  • Discuss current guidelines and clinical data on stroke prevention in patients with nonvalvular atrial fibrillation

  • Evaluate emerging novel oral anticoagulants and reversal therapies and their impact on the treatment landscape for nonvalvular atrial fibrillation

  • Assess optimal data on novel anticoagulant therapies that will help individualize appropriate treatment strategies

  • Describe the potential role of scoring assessments to properly risk stratify patients with atrial fibrillation, while considering stroke and bleeding risk

Faculty: R. Scott Wright, MD
Professor of Medicine
Mayo Clinic

Disclosure:

Dr. Wright serves on an advisory board/panel for Boehringer Ingelheim and Sanofi-Regeneron and receives research support from AstraZeneca, the Medicines Company, and Pfizer. His presentations have been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.
 

This activity is supported by educational grants from
Boehringer Ingelheim Pharmaceuticals and Bristol-Myers Squibb

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue